Journal of Hepatology
Volume 48, Issue 1 , Pages 20-27 , January 2008

Hospital admission is a relevant source of hepatitis C virus acquisition in Spain

  • Eva Martínez-Bauer

      Affiliations

    • Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Ciber de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
    • ,
  • Xavier Forns

      Affiliations

    • Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Ciber de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
    • Corresponding Author InformationCorresponding author. Present address: Liver Unit, ICMD, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain. Tel.: +93 227 54 99; fax: +93 451 55 22.
    • ,
  • Mercé Armelles

      Affiliations

    • Departament de Salut, Generalitat de Catalunya, Spain
    • ,
  • Ramon Planas

      Affiliations

    • Hospital Germans Trias i Pujol, Badalona, Spain
    • ,
  • Ricard Solà

      Affiliations

    • Hospital del Mar, Barcelona, Spain
    • ,
  • Mercé Vergara

      Affiliations

    • Corporació Sanitària Parc Taulí, Sabadell, Spain
    • ,
  • Silvia Fàbregas

      Affiliations

    • Hospital de Figueres, Girona, Spain
    • ,
  • Roser Vega

      Affiliations

    • Hospital de Figueres, Girona, Spain
    • ,
  • Javier Salmerón

      Affiliations

    • Hospital Universitario San Cecilio, Granada, Spain
    • ,
  • Moisés Diago

      Affiliations

    • Hospital General de Valencia, Spain
    • ,
  • Jose María Sánchez-Tapias

      Affiliations

    • Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Ciber de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
    • ,
  • Miquel Bruguera

      Affiliations

    • Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Ciber de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
    • ,
  • The Spanish Acute HCV Study Group

      Affiliations

    • V Andreu (Hospital de Mollet, Barcelona); C Baliellas (Hospital de Bellvitge, Hospitalet de Llobregat); R Barniol (Hospital General de Vic); M Berenguer (Hospital La Fe, Valencia); FJ Boada Casallo (Hospital Sagrat Cor, Barcelona); J Boadas (Hospital de Terrassa); M Bruguera (Hospital Clínic de Barcelona); M Diago (Hospital General de Valencia); J. Enriquez (Hospital de San Pau, Barcelona); S Fàbregas (Hospital de Figueres); X Forns (Hospital Clínic de Barcelona); J Genescà (Hospital Vall d’Hebron, Barcelona); J Giné Gala (Hospital Verge de la Cinta, Tortosa); E. Martínez-Bauer (Hospital Clinic, Barcelona); A Mas (Hospital Clinic, Barcelona); R Planas (Hospital Germans Trias I Pujol, Badalona); J Salmerón (Hospital Universitario San Cecilio, Granada); JM Sánchez-Tapias (Hospital Clínic de Barcelona); R Solà (Hospital del Mar, Barcelona); X Torras (Hospital San Pau, Barcelona); M Torres (Hospital L’Esperit Sant, Santa Coloma de Gramanet); R Vega (Hospital de Figueres); M Vergara (Corporació Sanitària Parc Tauli, Sabadell); LL Vidal (Hospital de Palamos, Girona).

Received 28 December 2006 ,Revised 18 June 2007 ,Accepted 5 July 2007.

References 

  1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562
  2. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36:S93–S98
  3. Bronowicki JP, Venard V, Botte C, Monhoven N, Gastin I, Chone L, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med. 1997;337:237–240
  4. Krause G, Trepka MJ, Whisenhunt RS, Katz D, Nainan O, Wiersma ST, et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol. 2003;24:122–127
  5. Bruguera M, Saiz JC, Franco S, Gimenez-Barcons M, Sanchez-Tapias JM, Fabregas S, et al. Outbreak of nosocomial hepatitis C virus infection resolved by genetic analysis of HCV RNA. J Clin Microbiol. 2002;40:4363–4366
  6. Widell A, Christensson B, Wiebe T, Schalen C, Hansson HB, Allander T, et al. Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Ann Intern Med. 1999;130:130–134
  7. Chiaramonte M, Stroffolini T, Lorenzoni U, Minniti F, Conti S, Floreani A, et al. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol. 1996;24:129–134
  8. Mele A, Spada E, Sagliocca L, Ragni P, Tosti ME, Gallo G, et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J Hepatol. 2001;35:284–289
  9. Des J, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19:S20–S25
  10. Stark K, Herrmann U, Ehrhardt S, Bienzle U. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Epidemiol Infect. 2006;134:814–819
  11. Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, et al. Prevalence and correlates of hepatitis C infection among users of North America’s first medically supervised safer injection facility. Public Health. 2005;119:1111–1115
  12. Roy KM, Hutchinson SJ, Wadd S, Taylor A, Cameron SO, Burns S, et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect. 2007;135:433–442
  13. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001;34:180–187
  14. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452–1457
  15. Forns X, Martinez-Bauer E, Feliu A, Garcia-Retortillo M, Martin M, Gay E, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology. 2005;41:115–122
  16. Sanchez-Tapias JM. Nosocomial transmission of hepatitis C virus. J Hepatol. 1999;31(Suppl 1):107–112
  17. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol. 2006;45:607–616
  18. Delwaide J, Bourgeois N, Gerard C, De Maeght S, Mokaddem F, Wain E, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther. 2004;20:15–22
  19. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88
  20. Morin T, Pariente A. Acute hepatitis C: a retrospective study of 62 cases. Gastroenterol Clin Biol. 2002;26:994–1000
  21. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003;35:104–113
  22. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250–256
  23. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43:1154–1159
  24. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–64
  25. Allander T, Gruber A, Naghavi M, Beyene A, Soderstrom T, Bjorkholm M, et al. Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet. 1995;345:603–607
  26. Forns X, Fernandez-Llama P, Pons M, Costa J, Ampurdanes S, Lopez-Labrador FX, et al. Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit. Nephrol Dial Transplant. 1997;12:736–740
  27. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel MA, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923–931
  28. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci. 1996;41:81S–85S

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(07)00527-2

doi: 10.1016/j.jhep.2007.07.031

Journal of Hepatology
Volume 48, Issue 1 , Pages 20-27 , January 2008

Article Tools